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Abstract  
 Albanian pharmaceutical market is a stable and regulated market. 
With a status of an EU candidate country, it is essential to adopt and 
transpose EU directives with domestic regulation. The aim of this study is to 
provide a panorama regarding pharmaceutical sector, by reflecting the 
specific elements that influence the demand and supply of product. It will be 
followed by a brief description regarding three major regulatory aspects that 
affect the activity of companies operating in it.  This study has two main 
pillars: Comparative analysis between Albania and Macedonia regarding the 
three main indicators of Health financing system; Competitiveness analysis, 
which consists in studying the competition between the constituent 
companies of the pharmaceutical sector in Albania. We calculate the four-
firm concentration ratio (CR4) and Herfindahl Hirschman Indexes (HHI). In 
the end we present the main findings from our study. 
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Introduction 
 Pharmacy practice in Europe, as a subject of study in itself, was 
organized in 1241. For thousands of years, empirical medicine and pharmacy 
were considered the same.  
 The pharmaceutical sector is a unique sector, which stands apart from 
the usual competition, for it is heavily regulated due to its critical importance 
to human welfare. To study the level of competition in this sector, one 
should necessarily analyze the demand and supply for the products offered in 
this market. On the demand side, apart from standard over-the counter 
medicine, we have a low level of individual consumers who exercise their 
freedom to choose between competing products based on features and 
relative prices. First, it can be argued with the low level of qualification of 
the customer to understand the pharmacological properties of these 
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ingredients although the exact chemical composition of medicines is 
mandatorily printed on the packaging. 
 Second, the products in this sector have features that consumers can 
not evaluate before use and in some cases the characteristics become difficult 
to identify even after use since the effects of the medication may not be 
apparent for a long time. It is important to mention that the drugs included in 
the category of goods are based on medical advice. To a great extent, 
therefore, demand is driven by the prescribing behavior of healthcare 
providers.  
 As a result consumers are not necessarily price sensitive. Another 
phenomenon often occurs in which pharmacists can substitute drugs with 
others or can either make descriptions of drugs to patients who are unwilling 
to go to a doctor. This reflects a very large distance to the final consumers by 
the manufacturers. Given that, many of these products are essential for 
human welfare, even making the difference between life and death, 
consumers are not price sensitive and are willing to sacrifice other 
consumption needs in order to incur healthcare expenses.  
 Even in developed countries this findings are relevant, but the 
situation in Albania is particularly delicate because of the greater lack of 
awareness, information, education among consumers and limited coverage of 
health insurance.  
 Once described the main elements that influence demand, the supply-
side pharmaceutical industry worldwide is dominated by a handful of firms; 
the dominance of reinforcing their market to the protection of the patent (for 
which they strive constantly to expand), higher advertising budgets and 
marketing led by health care providers who actually affect 'choice' of the 
customer. As pointed out in the pioneering study by Nanda and Khan (2006), 
there is the possibility of anti-competitive horizontal agreements at the level 
of producers as well as distributors, vertical agreements between producers 
and distributors in the supply chain and abuse of dominance arising out of 
patent protection. 
 In addition, one of the major factor that affect the development of 
each sector, is the process of regulatory development. Specifically, we will 
mention three key factors that influence this process in the pharmaceuticals: 
The first element is the licensing procedures for exercising the activity of 
wholesale, retail, import-export and production in the pharmaceutical sector. 
The second element relates to the statutory definition of reimbursable 
medicines and the third element relates to pricing policies. 
 In Albania, pharmaceutical sector is regulated by Law Nr. 105/2014 
"On Drugs and Pharmaceutical Service"1 
                                                          
1 This law is partly aligned with: Directive 2001/83 / EC of the European Parliament and 
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 This law establishes rules for the manufacture, placing on the market, 
import, export, marketing, use, marketing, quality control and inspection 
activities related to medicines for human use in the Republic of Albania, in 
order to ensure public health. This law applies to medicines for human use 
manufactured industrially, intended to be placed on the market in the 
Republic of Albania. Law nr.10383, 24.2.2011 "On compulsory insurance of 
health care in the Republic of Albania", lists reimbursable drugs as part of 
the compulsory insurance services. This package is compiled by determining 
among other things, the list of reimbursable drugs, as well as the extent of 
coverage of its drugs. The structure list of drugs is determined on the basis of 
the list of essential drugs, according to the classification INN (active 
principle of the drug), as defined by the World Health Organization. 
 The Council of Ministers nr.645 decision, 10.01.2014 "On the 
establishment and functioning of the price of drugs" regarding the price of 
medicines, sets that the price of drugs should be comparable to the price of 
five countries of the region (Macedonia, Greece, Italy, Serbia and Croatia) 
and can’t be higher than in those countries. Drug Prices Commission verifies 
the documentation of imported medicines, carried out and submitted to the 
National Agency for Medicines and Medical Equipment, during the past 12 
months. "The reference price for Albania" will be the lowest price of the 
following elements: a) the applied price of the five reference countries; b) the 
retail price of the drug in the origin country; c) the price of imported 
medicines in the Republic of Albania, during the past 12 months. The price 
of drugs on the market is controlled and based on CIF2 import prices 
declared by companies marketing authorization holder and on the basis of 
producer prices for medicines produced in the country, declared by the 
domestic producer. 
 
Health expenditure in Albania and Macedonia 
 In Western Balkan countries, the transition from socialism to 
capitalism and democracy was less smooth than in other parts of Emerging 
Europe. Upon completion of this stage they passed huge challenges in 
complete reorganization of their respective economies toward transformation 
                                                                                                                                                     
Council dated November 6, 2001 "on the Community code relating to medicinal products 
for human use" Number CELEX: 32001L0083, Official Journal of the European Union, 
Series L, Nr.311, dated 28. 11. 2001, p 67-128, as amended. Directive 2001/20 / EC of the 
European Parliament and the Council of 4 April 2001 "on the approximation of laws, 
regulations and administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use" . 
2 CIF import price "means the price” (Cost, Insurance, Freight - cost, insurance, 
transportation expense), designed to bar from the manufacturer or marketing authorization 
holder for crossing point of entry in the Republic of Albania. 
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into market economies, building the institutions to support the market 
economy, liberalizing prices, and privatizing many state- and socially-owned 
enterprises. What becomes more apparent is that there is a strong orientation 
towards the European Union (EU) in the Western Balkan States (WBS), 
leading to an effort to align pharmaceutical legislation with EU directives. 
As of early 2016, the six countries of the Western Balkans – Albania, Bosnia 
and Herzegovina, FYR Macedonia, Kosovo, Montenegro and Serbia – face a 
formidable array of challenges. 
 Health expenditures constitute one of the most important issues for 
the economies of most countries of the world. Expenses on this regard, 
having a high exert on public budgets, measure government investments in 
well-being and health of their citizens. Based on this argument, and 
especially embraced by the priror history of civil war and by the global 
economic crisis in the last decade, this issue is even more challenging for 
most Balkan countries. 
 Below we examine three important indicators of health financing 
system for two countries of Western Balkan, Albania and Macedonia. More 
specifically, the reports are: 1. Private expenditure on health as a percentage 
of total expenditure on health is a core indicator of health financing systems. 
This indicator contributes to understanding the relative weight of private 
entities in total expenditure on health. It includes expenditure from pooled 
resources with no government control, such as voluntary health insurance, 
and the direct payments for health by corporations (profit, non-for-profit and 
NGOs) and households. 2. General government expenditure on health as a 
percentage of total government expenditure contributes to understand the 
weight of public spending on health within the total value of public sector 
operations. It includes not just the resources channeled through government 
budgets but also the expenditure on health by extra-budgetary entities and 
notably the compulsory health insurance. 3. External resources for health as 
a percentage of total expenditure on health traces the financing flows from 
external sources who provide the funds to public and private financing 
agents. It includes in kind and in cash resources provided as loans and grants. 
This is, however, an indicator which refers to the origin of the resources used 
to purchase health services.  
 These data are generated from sources that World Health 
Organization (WHO), has been collecting for over ten years. The most 
comprehensive and consistent data on health financing is generated from 
national health accounts.3 In Albania, as shown in the table 1.dominates the 
                                                          
3 The principal international references used are the EUROSTAT database, International 
Monetary Fund (IMF) international financial statistics; OECD health data. National sources 
include: National health accounts (NHA) reports, national accounts (NA) reports, general 
government (GG) accounts, public expenditure reviews (PER), notably social security and 
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first report reflecting the high importance of private expenditure on health, 
reflecting an annual average rate of 19.5% higher than Macedonia. As for the 
second indicator we see a slightly higher and stable rate of Macedonia 
against Albania with an average annual rate of 5% higher. 
 
Albania 
 
Table 1: Author‘s calculations based on the World Health Organization database  
 
Macedonia 
 
Table 2: Author‘s calculations based on the World Health Organization database  
 
 Despite the fact that in both countries the ratio is not high, it is 
concluded that in Albania the public expenditure allocated on health to the 
total government expenditure is lower than in Macedonia. It is shown that in 
Albania private expenditure on health was slightly higher than governmental. 
And finally, the third report calculated is approximately the same for both 
countries, with a slight fluctuation of 1.6% in average annual rate in Albania. 
 
Albanian pharmaceutical market and competitiveness study 
 Albanian pharmaceutical market is a stable and regulated market. 
Currently there are about 100 pharmaceutical companies which are 
distributors of pharmaceutical products and only few of them are producers. 
                                                                                                                                                     
other health insurance compulsory agencies. 
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About this total, 22 companies are counted as large tax payers, based on the 
internal regulations of the General Directorate of Tax where largest 
taxpayers (known as VIP), have a turnover of more than 250 million ALL 
(approximately 1.8 million EUR). The total sales of these companies for 
2014 is 23,264,972,209 ALL4. The dominance of these companies in the 
pharmaceutical market has been present for years. A part of the study is 
going to examine the degree of concentration of the four most important 
companies in the sector that indices of how fragmented the market is 
structured. Market structure varies from one extreme where perfect 
competition exists with many producers or sellers and easy market entry and 
exit. The other market extreme is a monopoly with effective barriers to entry 
of a competitor. The tendency toward a monopoly or a market with 
monopolistic characteristics or power is the focus of most studies using 
concentration indices.  
 The study will be based on the calculation of the four-firm 
concentration ratio (CR4) and Herfindahl Hirschman Indexes (HHI). The 
four-firm concentration ratio is an indicator of the size (as measured by 
output or sales) of the four largest firms within an industry, compared to the 
output of the entire industry. It is determined as follows:  
CR4 = (X1 + X2 + X3 + X4) / T 
 Where, Xn is the sale of the nth largest firm and T is the total sales of 
the industry. 
 The selected evaluation period is 2012- 2014. The calculation will be 
based on the identification of four companies which have a higher level of 
sales for the period selected. We make two assumptions to perform 
calculations. The first will be based on the actual sales of the 22 VIP 
companies in the pharmaceutical sector. And the second will be based on 
estimated data for all sector companies including actual data for 22 large 
companies and assuming a total sales level for 78 other companies as the 
maximum potential limit sales of 250 million. 
 In table 3 are presented the calculation of CR4 indicators for four 
biggest companies in the sector. Calculations are made on the factual data of 
22 large companies. 
 
 
 
 
 
 
                                                          
4 The data calculated by the author on the financial statements of companies stated in 
Regional Tax Directorate of Large Taxpayers 
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Year 2012 Year 2013 Year 2014 
Sales (company 1)/ total sales (%) 17.35 16.55 14.37 
Sales (company 2)/ total sales (%) 9.94 12.33 13.04 
Sales (company 3)/ total sales (%) 3.96 4.73 9.04 
Sales (company 4)/ total sales (%) 10.53 9.64 7.81 
Total 41.78% 43.25% 44.26% 
Total Sales 100 100 100 
CR4 41.80% 44.30% 44.30% 
Table 3:  Author calculations based on financial statement data 
 
 In table 4, is presented the calculation of CR4 for four biggest 
companies making sector estimates of total sector sales including factual data 
of 22 large companies (VIP) and estimated data for 78 other not large 
companies (non-VIP). 
 
Year 2012 Year 2013 Year 2014 
Sales (company 1)/ total estimated sales 
(%) 8.95 8.95 7.82 
Sales (company 2)/ total estimated sales 
(%) 5.13 6.67 7.1 
Sales (company 3)/ total estimated sales 
(%) 2.05 2.56 4.92 
Sales (company 4)/ total estimated sales 
(%) 5.44 5.21 4.25 
Total 21.56% 23.39% 24.08% 
Total estimated Sales 100 100 100 
CR4 21.56% 23.39% 24.08% 
Table 4:  Author calculations based on financial statement data and estimated data 
 
 As in the first case and the second case, the generated results indicate 
a low level of concentration between 0% -50% which reflects a position 
between perfect competition and oligopoly.  
 The Herfindahl- Hirschman Index provides a more complete picture 
of industry concentration than does the concentration ratio. The HHI uses the 
market shares of all the companies in the industry, and these market shares 
are squared in the calculation to place more weight on the larger companies. 
If there are n companies in the industry, the HHI can be expressed: 
 HHI =10,000* (s12 + s22 + s32 + …. + sn2) 
 Where si is the market share of the ith company 
 The calculations for the three years are given in the following tables 
for 100 companies of the sector. 
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Table 5:  Author calculations based on financial statement data and estimated data 
 
 We note that for 22 larger companies are using real data taken from 
actual financial statement of companies, for smaller ones we are assuming a 
maximum potential level sales of 250 million ALL. Choosing this limit helps 
us to determine the potential level of competitiveness of selected sectors. The 
minimum level of the index which would reflect the full competition is: HHI 
min = 1002 / nr. Companies = 100 
 We see from the results obtained that the level of index for the past 
three years is closer to 100 than 10,000 which indicate a low level of market 
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concentration. The annual change rate for the period 2012-2013 is 0.17 times 
and the annual change rate in 2013-2014 is declining by 0.06 times.  
 Practically index values would be higher than the values listed in the 
table because the study assumed a maximum level of value sales for 
companies that do not appear as large taxpayers. Given that the greater 
weight of the sector (about 80%) is dominated by 22 studied companies, 
theoretical calculated assessment comes close to the actual market value. 
 
Conclusion 
 After studying the main elements that characterize the pharmaceutical 
market in Albania and especially after analyzing the level of competitiveness 
of the constituent companies, we come to these conclusions.  
 First, the pharmaceutical market in Albania is a regulated and stable 
and market. Most of this market currently is dominated by 22 companies that 
are counted as large tax payers, based on the internal regulations of the 
General Directorate of Tax. Although entry and exit barriers in the sector are 
low, the specific characteristics of the activity within this sector show that 
the number of participating companies is stable over the years.  
 Second, the generated results indicate a low level of concentration 
between 0% -50% which reflects a position between perfect competition and 
oligopoly. Also, from the results obtained from HHI we saw that the level of 
index for the past three years is closer to 100 than 10,000 which indicate a 
low level of market concentration. 
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Appendix: 
 In Appendix we present a summary of data on which the paper is 
supported. The data for the first 22 companies are generated by companies' 
financial statements submitted to the General Tax Directorate. For other 
companies which are small in this sector, we get the level of estimated sales 
of 250 million ALL. On these data are calculated CR4 and HHI index.  
 
 
Sales per Year 
Company 2012 2013 2014 
1 1,268,085,995 1,103,764,140 1,254,581,516 
2 344,048,351 354,229,566 317,938,134 
3 706,404,503 757,841,196 794,359,536 
4 697,207,449 662,152,997 579,802,147 
5 3,606,166,848 3,799,673,436 3,342,767,360 
6 888,488,169 857,488,717 977,834,903 
7 912,057,913 862,967,569 896,518,571 
8 824,183,453 742,328,748 825,517,343 
9 712,980,398 741,046,868 631,958,374 
10 1,049,141,783 1,139,636,859 948,741,320 
11 2,189,943,698 2,211,792,937 1,816,922,339 
12 853,313,946 748,177,984 912,295,348 
13 835,093,691 1,014,655,452 840,145,508 
14 361,173,463 370,484,984 341,124,840 
15 876,562,627 809,626,348 787,512,056 
16 360,309,564 274,162,715 286,789,620 
17 675,984,407 852,414,300 919,698,371 
18 824,166,421 1,086,531,183 2,102,507,184 
19 2,065,723,559 2,830,864,574 3,034,257,529 
20 256,114,677 263,200,820 346,324,968 
21 482,222,726 386,921,249 296,021,763 
22   1,084,933,830 1,011,353,479 
Total (ALL) 20,789,373,641 22,954,896,471 23,264,972,209 
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Sales per Year 
Company 2012 2013 2014 
1 1,268,085,995 1,103,764,140 1,254,581,516 
2 344,048,351 354,229,566 317,938,134 
3 706,404,503 757,841,196 794,359,536 
4 697,207,449 662,152,997 579,802,147 
5 3,606,166,848 3,799,673,436 3,342,767,360 
6 888,488,169 857,488,717 977,834,903 
7 912,057,913 862,967,569 896,518,571 
8 824,183,453 742,328,748 825,517,343 
9 712,980,398 741,046,868 631,958,374 
10 1,049,141,783 1,139,636,859 948,741,320 
11 2,189,943,698 2,211,792,937 1,816,922,339 
12 853,313,946 748,177,984 912,295,348 
13 835,093,691 1,014,655,452 840,145,508 
14 361,173,463 370,484,984 341,124,840 
15 876,562,627 809,626,348 787,512,056 
16 360,309,564 274,162,715 286,789,620 
17 675,984,407 852,414,300 919,698,371 
18 824,166,421 1,086,531,183 2,102,507,184 
19 2,065,723,559 2,830,864,574 3,034,257,529 
20 256,114,677 263,200,820 346,324,968 
21 482,222,726 386,921,249 296,021,763 
22 250,000,000 1,084,933,830 1,011,353,479 
23 250,000,000 250,000,000 250,000,000 
24 250,000,000 250,000,000 250,000,000 
… 250,000,000 250,000,000 250,000,000 
… 250,000,000 250,000,000 250,000,000 
… 250,000,000 250,000,000 250,000,000 
98 250,000,000 250,000,000 250,000,000 
99 250,000,000 250,000,000 250,000,000 
100 250,000,000 250,000,000 250,000,000 
Total (ALL) 40,289,373,641 42,454,896,471 42,764,972,209 
 
  
